Kant S, Habbach A, Gapud EJ, et al. - Among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) with severe renal disease, researchers analyzed the outcomes of treatment with sequential therapy (ST) starting with (GC) and oral (CYC) followed by transition to (RTX). Birmingham Vasculitis Activity Score (BVAS) of zero by 6 months was defined as complete remission, which was evaluated as the primary outcome. At the time of diagnosis, the median BVAS was 15. Participants were observed for a median duration of 44 months. Remission was achieved by all patients. Pneumonia and bone marrow suppression was experienced as adverse events by 2 patients and 3 patients, respectively. No deaths were reported. Findings revealed the effectiveness of ST with GC and CYC followed by RTX for AAV patients with severe renal disease. The observed therapy-associated adverse events were comparable to other studies.